Aurora Cannabis urges shareholders to take no action on Curaleaf hostile bid
ACB•Aurora points to recent international growth
Aurora cited fiscal Q1 2027 international net revenue growth of 17% year over year, with Germany a key driver.
The group recently expanded in the UK through the acquisitions of Internode Pharma and HAP Pharma.
Aurora responds to Curaleaf's unsolicited bid
Aurora Cannabis urged shareholders to take no action on Curaleaf's unsolicited take-over bid, which targets Aurora's EU-GMP manufacturing network and global medical cannabis footprint.
Aurora said it has set up a special committee of independent directors to review the proposal with financial and legal advisers. The offer is open for at least 105 days from the start of the bid.
